[Pharmacokinetics of mezlocillin. Comparison with ampicillin and influence of probenecid (author's transl)]. 1982

L Verbist, and T B Tjandramaga, and R Verbesselt, and P J de Schepper

In a randomized cross-over study 10 healthy male volunteers received a single 1 g dose of 6-[R]-2-3-methylsulfonyl -2- oxo-imidazolisine -1- carboxamido) -2- phenyl-acetamido]-penicillanic acid sodium salt (mezlocillin) and of ampicillin, either intravenously or intramuscularly. Following the intravenous loading dose, mean peak serum levels of 101 micrograms/ml for mezlocillin and 91.5 micrograms/ml for ampicillin were recorded. The ultimate half-life t 1/2 of mezlocillin (46.4 min) was slightly shorter than that of ampicillin (52.4 min). Similarly, the total volume of distribution of mezlocillin (24.1 l) was slightly inferior to that of ampicillin (29.4 l). The proportions of the dose administered recovered in the urine of 24 hours were 50.4 % for mezlocillin and 69.9 % for ampicillin. The total clearances of the two antibiotics were not significantly different, but the renal clearance of mezlocillin (186.6 ml/min/1.73 m2) was significantly lower than that of ampicillin (309.5 ml/min/1.73 m2). Following intramuscular injection, the mean peak serum levels obtained were 15.6 microgram/ml with mezlocillin and 15.1 micrograms/ml with ampicillin. The half-lives of the antibiotics were 50.0 min and 57.2 min respectively. The bioavailable fractions of mezlocillin and ampicillin, as measured from the areas under the serum concentration curves wer 63 % and 75 % respectively of the values determined after intravenous injection. The oral administration of 1 g probenecid one hour before an intramuscular injection of mezlocillin increased the peak serum level and area under the curve by 65 % and decreased the total clearance, renal clearance and apparent volume of distribution by 38 %, 52 %, and 35 % respectively. However, the ultimate half-life was not significantly altered (50.5 min without, and 52.0 min with probenecid).

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008802 Mezlocillin Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections. Bay-f 1353,Baypen,Melocin,Meslocillin,Mezlin,Mezlocillin Sodium,Mezlocilline,Bay f 1353,Bayf 1353,Sodium, Mezlocillin
D010406 Penicillins A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065) Antibiotics, Penicillin,Penicillin,Penicillin Antibiotics
D011339 Probenecid The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. Benecid,Benemid,Benuryl,Pro-Cid,Probecid,Probenecid Weimer
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

L Verbist, and T B Tjandramaga, and R Verbesselt, and P J de Schepper
January 1980, Archives of oto-rhino-laryngology,
L Verbist, and T B Tjandramaga, and R Verbesselt, and P J de Schepper
January 1976, Arzneimittel-Forschung,
L Verbist, and T B Tjandramaga, and R Verbesselt, and P J de Schepper
February 1982, La Nouvelle presse medicale,
L Verbist, and T B Tjandramaga, and R Verbesselt, and P J de Schepper
March 1978, The Japanese journal of antibiotics,
L Verbist, and T B Tjandramaga, and R Verbesselt, and P J de Schepper
February 1982, La Nouvelle presse medicale,
L Verbist, and T B Tjandramaga, and R Verbesselt, and P J de Schepper
February 1982, La Nouvelle presse medicale,
L Verbist, and T B Tjandramaga, and R Verbesselt, and P J de Schepper
January 1979, Arzneimittel-Forschung,
L Verbist, and T B Tjandramaga, and R Verbesselt, and P J de Schepper
April 1981, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
L Verbist, and T B Tjandramaga, and R Verbesselt, and P J de Schepper
August 1983, European journal of clinical microbiology,
L Verbist, and T B Tjandramaga, and R Verbesselt, and P J de Schepper
February 1982, La Nouvelle presse medicale,
Copied contents to your clipboard!